HPTN 069 / ACTG A5305
Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in U.S. Women...."NO new infections....annual incidence rate 0%"
" No new infections"
" Annual incidence rate 0% [95% CI: 0%, 2.5"
Reported by Jules Levin
IAC/Durban 2016 July 18-22
Roy M. Gulick, MD, MPH
Rochelle Belfer Professor in Medicine
Weill Medical College of Cornell University
for the HPTN 069/ACTG A5305 Team
